Blood–brain barrier permeable β-blockers linked to lower risk of Alzheimer’s disease in hypertension
Brain · 01.03.2023 · 146 (3) · 1141-1151
DOI: 10.1093/brain/awac076 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, online erschienen am 23.02.2022. Verfasst von Emily Eufaula Beaman und 8 weiteren Autor:innen. Beteiligte Einrichtung: Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen Ø, Denmark. Hauptthemen laut MEDLINE: Alzheimer Disease, Hypertension. Die Arbeit wurde bisher 87-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: European Union’s Horizon 2020, Marie Skłodowska-Curie, Savværksejer Jeppe Juhls og hustru Ovita Juhls Mindelegat.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease is a neurodegenerative disorder in which the pathological accumulation of amyloid-β and tau begins years before symptom onset. Emerging evidence suggests that β-blockers (β-adrenergic antagonists) increase brain clearance of these metabolites by enhancing CSF flow. Our objective was to determine whether β-blocker treatments that easily cross the blood–brain barrier reduce the risk of Alzheimer's disease compared to less permeable β-blockers. Data from the Danish national registers were used to identify a retrospective cohort of individuals with hypertension, and those treated with β-blockers were included in the analysis. People with indications for β-blocker use other than hypertension (e.g. heart failure) were only retained in a sensitivity analysis. β-blockers were divided into three permeability groups: low, moderate and high. We used multivariable cause-specific Cox regression to model the effect of β-blocker blood–brain barrier permeability on time to dementia outcomes, adjusting for baseline comorbidities, demographics and socioeconomic variables. Death was modelled as a competing risk. The 10-year standardized absolute risk was estimated as the averaged person-specific risks per treatment. In a cohort of 69 081 (median age = 64.4 years, 64.8% female) people treated with β-blockers for hypertension, highly blood–brain barrier-permeable β-blockers were associated with reduced risk of Alzheimer's disease versus low permeability β-blockers (−0.45%, P < 0.036). This effect was specific to Alzheimer's diagnoses and did not extend to dementia in general. Propensity score analysis matching high and low blood–brain barrier-permeable patients also detected a decreased Alzheimer's risk (−0.92%, P < 0.001) in the high permeability group compared to the low, as did a 1-year landmark analysis (−0.57%, P < 0.029) in which events within the first year of follow-up were ignored as likely unrelated to treatment. Our results suggest that amongst people taking β-blockers for hypertension, treatment with highly blood–brain barrier permeable β-blockers reduces the risk of Alzheimer's disease compared to low permeability drugs. Our findings support the hypothesis that highly permeable β-blockers protect against Alzheimer's disease by promoting waste brain metabolite clearance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen Ø, Denmark.
- Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen N, Denmark.
- Department of Cardiology, Copenhagen University Hospital Herlev-Gentofte, 2900 Hellerup, Denmark.
- Department of Public Health, Section of Biostatistics, University of Copenhagen, 1353 Copenhagen K, Denmark.
- Center for Translational Neuromedicine, Faculty of Health and Medical Sciences (SUND), University of Copenhagen, 2200 Copenhagen N, Denmark.
- Center for Translational Neuromedicine, Department of Neurosurgery, University of Rochester Medical Center, Rochester, NY 14642, USA.
ORCID-Profile: Emily Eufaula Beaman, Sebastian Camillo Holst
Förderung
- European Union’s Horizon 2020
- Marie Skłodowska-Curie
- Savværksejer Jeppe Juhls og hustru Ovita Juhls Mindelegat
- Independent Research Fund Denmark
- Lundbeck Foundation
Zitieren
APA
Beaman, E. E., Bonde, A. N., Larsen, S. M. U., Ozenne, B., Lohela, T. J., Nedergaard, M., Gíslason, G. H., Knudsen, G. M., & Holst, S. C. (2023). Blood–brain barrier permeable β-blockers linked to lower risk of Alzheimer’s disease in hypertension. Brain, 146(3), 1141-1151. https://doi.org/10.1093/brain/awac076
Vancouver
Beaman EE, Bonde AN, Larsen SMU, Ozenne B, Lohela TJ, Nedergaard M, et al. Blood–brain barrier permeable β-blockers linked to lower risk of Alzheimer’s disease in hypertension. Brain. 2023;146(3):1141-1151. doi:10.1093/brain/awac076
BibTeX
@article{Beaman2023,
author = {Beaman, Emily Eufaula and Bonde, Anders Nissen and Larsen, Sara Marie Ulv and Ozenne, Brice and Lohela, Terhi Johanna and Nedergaard, Maiken and Gíslason, Gunnar Hilmar and Knudsen, Gitte Moos and Holst, Sebastian Camillo},
title = {Blood–brain barrier permeable β-blockers linked to lower risk of Alzheimer’s disease in hypertension},
journal = {Brain},
year = {2023},
volume = {146},
number = {3},
pages = {1141--1151},
doi = {10.1093/brain/awac076}
}
EUVIMED